Scientific publication – IMMAGINA new tools on bioRxiv – 10/2018
Our preprint work describing new probes to sense the activity of protein synthesis and to capture associated RNA is now available on bioRxiv
Immagina Biotechnology has been featured by… (2017)
The Next Tech – World Cancer Day And local media are sometimes important to help the local business community…
New patent / Novel agarose-based graphene beads and uses thereof – 09/2017
We announce a new patent describing new tools for specific catalytic reactions, adsorption and separation of molecules. New achievements in chemistry, biotechnology and environmental fields are now possible!
Scientific Publication – 08/2017
Our first paper reporting the basic of our RiboLace technology Active ribosome profiling with RiboLace is now public available on bioRxiv. The paper describes a novel method based on an original puromycin-containing molecule capable of isolating active ribosomes by means of an antibody-free and tag-free pull-down approach. RiboLace is fast, works reliably with low amounts of input material, […]
Our beads are now on the market! – 03.2017
see Beads Galaxy
Publications from our scientific community (2017)
Viero’s Lab published In vivo translatome profiling reveals early defects in ribosome biology underlying SMA pathogenesis in bioRxivpreprint. The results described suggest that neuronal tissues and cells are particularly sensitive to perturbations in translation during SMA, and identify ribosome biology as an important, yet largely neglected, factor in motor neuron degeneration
Immagina Biotechnology has been featured by… (Nov, 2016)
FINSMES http://www.finsmes.com/2016/11/immagina-biotechnology-raises-e480k-in-funding.html Immagina Biotechnology has developed a patented technology, called RiboLace, which enables users to better understand how cells works, with applications in the fiels of personalized medicine research. The company is currently working in advancing studies in the field of cancer and neurodegenerative diseases and its products can be acquired by research labs and […]
Immagina Biotechnology s.r.l. raises € 0.48 million, Nov 2016
28th November 2016, Immagina Biotechnology s.r.l, a privately held company that is developing the first technology for active ribosomes isolation, today announced that it has raised €0.48 million in new funding. The round was funded by existing investors, Harald Oberrauch (Technicon S.p.A.), and Hermann Hauser Investment Gmbh
ITALIAN TRADE ASSOCIATION – TRADE MISSION TO BOSTON AND SAN FRANCISCO, Oct 2015
Immagina BioTechnology has been selected by the Italian Trade Agency for a trade mission to San Francisco and Boston. We had the opportunity to speak in a showcase eventat at the CIC and at J&J. We experienced a thrilling business opportunity! We thank the organisation for planning great meetings with leading invited speakers and for organizing networking […]
Publications from the IMMAGINA scientific network (2015)
Our new collaborative paper Global translation variations in host cells upon attack of lytic and sublytic Staphylococcus aureus α-haemolysin has been published in Biochemical Journal. Our results reveal the importance of translational control during host-pathogen interaction. Viero’s Lab published RiboAbacus: a model trained on polyribosome images predicts ribosome density and translational efficiency from mammalian transcriptomes in Nucleic Acids Research. RiboAbacus is […]